Filing Flows › Gossamer Bio (GOSS) › Q2 2026 › vs Q2 2025
Gossamer Bio (GOSS) Q2 2026 vs Q2 2025 (year over year)
Gossamer Bio's revenue fell $2.3M (-20%) from $11.5M in Q2 2025 to $9.2M in Q2 2026.
Gossamer Bio, Q2 2026: revenue $9.2M (-20% year over year), operating margin -282.2%, net earnings $16.9M, operating cash flow −$39.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $9.2M | $11.5M | −$2.3M | -20% |
| Other income, net | $43.0M | $492K | $42.5M | 87× |
| Costs & expenses | $52.2M | $50.3M | $2.0M | +4% |
| Operating costs | $35.3M | $50.3M | −$14.9M | -30% |
| Net earnings | $16.9M | −$38.3M | $55.2M | — |
| Research & development | $26.4M | $41.6M | −$15.2M | -36% |
| General & admin | $8.9M | $8.7M | $221K | +3% |
| Operating cash sources | $58.8M | $11.4M | $47.4M | +417% |
| Share-based compensation | $2.5M | $2.6M | −$123K | -5% |
| Cash used in operations | $39.4M | $47.1M | −$7.6M | -16% |
| Working capital & other | $58.8M | $11.4M | $47.4M | +417% |
Questions
How much did Gossamer Bio's revenue grow year over year in Q2 2026?
Gossamer Bio's revenue fell $2.3M (-20%) from $11.5M in Q2 2025 to $9.2M in Q2 2026.